VYOME HOLDINGS, INC.

HIND ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-10.3M $-1.4M $-11.4M $-46.2M $-63.1M $-21.6M $-23.7M $-37.4M
Depreciation & Amortization $12.0K $17.3K $340.0K $479.0K
Depreciation $22.0K $121.0K $330.0K $232.0K $15.0K $400.0K $581.0K
Amortization $0 $33.0K $1.8M $1.7M $1.7M
Stock-Based Compensation $577.1K $184.0K $766.0K $2.1M $12.2M $1.3M $3.0M $4.7M
Net Cash from Operating Activities $-3.7M $-614.1K $-17.0M $-21.9M $-15.4M $-8.6M $-22.9M $-29.4M
Investing Activities
Capital Expenditures $43.0K $131.0K $352.0K $171.0K $194.0K $1.3M
Business Acquisitions $25.4M
Net Cash from Investing Activities $315 $-10.0K $-92.0K $1.9M $-2.4M $2.4M $19.5M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $8.7M $698.0K $17.6M $3.1M $33.3M $11.1M $13.4M $10.0M
Net Change in Cash $4.9M $85.3K $604.0K $-18.9M $19.8M $22.0K $-7.1M $79.0K
Free Cash Flow $-17.0M $-22.0M $-15.7M $-8.7M $-23.1M $-30.7M
← Newer Page 1 of 2 Older →